Corvus Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
Corvus Pharmaceuticals, Inc. (CRVS) reported Increase (Decrease) in Accounts Payable of $1.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$650.00K, a 135.54% decline year-over-year.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.21M.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $517.00K, a 27.08% decline year-over-year.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.16M, a 276.21% decline year-over-year.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$91.00K, a 108.61% decline from fiscal 2024.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.06M.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$451.00K, a 209.73% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2022 was $411.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 11 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$650.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.56M 10-Q · filed 2026-08-06 | $2.07M derived: sum of 3 quarters · filed 2026-08-06 | $910.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $2.21M 10-Q · filed 2026-05-07 | $2.72M derived: sum of 2 quarters · filed 2026-05-07 | $1.56M derived: sum of 3 quarters · filed 2026-05-07 | $3.39M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $517.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$646.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.18M derived: sum of 3 quarters · filed 2026-08-06 | -$91.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $666.00K derived: sum of 2 quarters · filed 2026-08-06 | -$608.00K 10-Q · filed 2025-11-04 | $101.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $555.00K 10-Q · filed 2026-08-06 | $1.26M derived: sum of 3 quarters · filed 2026-08-06 | $1.92M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$1.27M 10-Q · filed 2026-05-07 | -$565.00K derived: sum of 2 quarters · filed 2026-05-07 | $95.00K derived: sum of 3 quarters · filed 2026-05-07 | -$301.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $709.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.37M derived: sum of 2 quarters · filed 2026-03-12 | $973.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.06M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $660.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $264.00K derived: sum of 2 quarters · filed 2025-11-04 | $348.00K 10-Q · filed 2025-11-04 | $469.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | -$396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$312.00K 10-Q · filed 2025-08-07 | -$191.00K derived: sum of 3 quarters · filed 2026-03-12 | -$885.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | $84.00K 10-Q · filed 2025-05-08 | $205.00K derived: sum of 2 quarters · filed 2026-03-12 | -$489.00K derived: sum of 3 quarters · filed 2026-03-12 | $202.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$573.00K derived: sum of 2 quarters · filed 2026-03-12 | $118.00K derived: sum of 3 quarters · filed 2026-03-12 | -$451.00K 10-K · filed 2026-03-12 | |
| 2023-09-30 | -$694.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.00K derived: sum of 2 quarters · filed 2024-11-12 | -$572.00K 10-Q · filed 2024-11-12 | -$2.82M derived: sum of 4 quarters · filed 2025-03-25 | |
| 2023-06-30 | $691.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $122.00K 10-Q · filed 2024-08-06 | -$2.13M derived: sum of 3 quarters · filed 2025-03-25 | -$301.00K derived: sum of 4 quarters · filed 2025-03-25 | |
| 2023-03-31 | -$569.00K 10-Q · filed 2024-05-07 | -$2.82M derived: sum of 2 quarters · filed 2025-03-25 | -$992.00K derived: sum of 3 quarters · filed 2025-03-25 | -$782.00K derived: sum of 4 quarters · filed 2025-03-25 | |
| 2022-12-31 | -$2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$423.00K derived: sum of 2 quarters · filed 2025-03-25 | -$213.00K derived: sum of 3 quarters · filed 2025-03-25 | $411.00K 10-K · filed 2025-03-25 | |
| 2022-09-30 | $1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.04M derived: sum of 2 quarters · filed 2023-11-07 | $2.66M 10-Q · filed 2023-11-07 | $1.89M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $834.00K 10-Q · filed 2023-08-08 | $65.00K derived: sum of 3 quarters · filed 2024-03-19 | -$466.00K derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | $624.00K 10-Q · filed 2023-05-08 | -$145.00K derived: sum of 2 quarters · filed 2024-03-19 | -$676.00K derived: sum of 3 quarters · filed 2024-03-19 | -$2.72M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | -$769.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$1.30M derived: sum of 2 quarters · filed 2024-03-19 | -$3.35M derived: sum of 3 quarters · filed 2024-03-19 | -$1.90M 10-K · filed 2024-03-19 | |
| 2021-09-30 | -$531.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.58M derived: sum of 2 quarters · filed 2022-11-03 | -$1.13M 10-Q · filed 2022-11-03 | -$237.00K derived: sum of 4 quarters · filed 2023-03-28 | |
| 2021-06-30 | -$2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$602.00K 10-Q · filed 2022-08-08 | $294.00K derived: sum of 3 quarters · filed 2023-03-28 | $86.00K derived: sum of 4 quarters · filed 2023-03-28 | |
| 2021-03-31 | $1.44M 10-Q · filed 2022-05-05 | $2.34M derived: sum of 2 quarters · filed 2023-03-28 | $2.13M derived: sum of 3 quarters · filed 2023-03-28 | $1.55M derived: sum of 4 quarters · filed 2023-03-28 | |
| 2020-12-31 | $896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $688.00K derived: sum of 2 quarters · filed 2023-03-28 | $111.00K derived: sum of 3 quarters · filed 2023-03-28 | $1.02M 10-K · filed 2023-03-28 | |
| 2020-09-30 | -$208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | -$785.00K derived: sum of 2 quarters · filed 2021-11-01 | $123.00K 10-Q · filed 2021-11-01 | $661.00K derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | -$577.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $331.00K 10-Q · filed 2021-08-02 | $869.00K derived: sum of 3 quarters · filed 2022-03-10 | $141.00K derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | $908.00K 10-Q · filed 2021-04-29 | $1.45M derived: sum of 2 quarters · filed 2022-03-10 | $718.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.09M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | $538.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$190.00K derived: sum of 2 quarters · filed 2022-03-10 | $184.00K derived: sum of 3 quarters · filed 2022-03-10 | $450.00K 10-K · filed 2022-03-10 | |
| 2019-09-30 | -$728.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$354.00K derived: sum of 2 quarters · filed 2020-10-29 | -$88.00K 10-Q · filed 2020-10-29 | $25.00K derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-06-30 | $374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $640.00K 10-Q · filed 2020-07-30 | $753.00K derived: sum of 3 quarters · filed 2021-03-25 | $383.00K derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-03-31 | $266.00K 10-Q · filed 2020-04-30 | $379.00K derived: sum of 2 quarters · filed 2021-03-25 | $9.00K derived: sum of 3 quarters · filed 2021-03-25 | -$1.24M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2018-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$257.00K derived: sum of 2 quarters · filed 2021-03-25 | -$1.50M derived: sum of 3 quarters · filed 2021-03-25 | -$1.46M 10-K · filed 2021-03-25 | |
| 2018-09-30 | -$370.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | -$1.61M derived: sum of 2 quarters · filed 2019-10-29 | -$1.57M 10-Q · filed 2019-10-29 | -$1.73M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2018-06-30 | -$1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$1.20M 10-Q · filed 2019-08-01 | -$1.36M derived: sum of 3 quarters · filed 2020-03-09 | -$1.97M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2018-03-31 | $45.00K 10-Q · filed 2019-05-09 | -$113.00K derived: sum of 2 quarters · filed 2020-03-09 | -$723.00K derived: sum of 3 quarters · filed 2020-03-09 | $1.04M derived: sum of 4 quarters · filed 2020-03-09 | |
| 2017-12-31 | -$158.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$768.00K derived: sum of 2 quarters · filed 2020-03-09 | $995.00K derived: sum of 3 quarters · filed 2020-03-09 | $1.55M 10-K · filed 2020-03-09 | |
| 2017-09-30 | -$610.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.15M derived: sum of 2 quarters · filed 2018-11-01 | $1.71M 10-Q · filed 2018-11-01 | $1.10M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $2.32M 10-Q · filed 2018-08-02 | $1.71M derived: sum of 3 quarters · filed 2019-03-07 | $2.71M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2017-03-31 | $559.00K 10-Q · filed 2018-05-03 | -$54.00K derived: sum of 2 quarters · filed 2019-03-07 | $948.00K derived: sum of 3 quarters · filed 2019-03-07 | $1.27M derived: sum of 4 quarters · filed 2019-03-07 | |
| 2016-12-31 | -$613.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $389.00K derived: sum of 2 quarters · filed 2019-03-07 | $711.00K derived: sum of 3 quarters · filed 2019-03-07 | $518.00K 10-K · filed 2019-03-07 | |
| 2016-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $1.32M derived: sum of 2 quarters · filed 2017-11-02 | $1.13M 10-Q · filed 2017-11-02 | $1.93M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $322.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $129.00K 10-Q · filed 2017-08-03 | $926.00K derived: sum of 3 quarters · filed 2018-03-01 | $1.07M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | -$193.00K 10-Q · filed 2017-05-04 | $604.00K derived: sum of 2 quarters · filed 2018-03-01 | $747.00K derived: sum of 3 quarters · filed 2018-03-01 | $1.02M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | $797.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $940.00K derived: sum of 2 quarters · filed 2018-03-01 | $1.21M derived: sum of 3 quarters · filed 2018-03-01 | $1.24M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $414.00K derived: sum of 2 quarters · filed 2016-11-03 | $443.00K 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $300.00K 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $29.00K 10-Q · filed 2016-05-05 | ||||
| 2014-12-31 | $57.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |